Updated:
Puhui Brilliance Fund
Zhe Ji founded Puhui Brilliance Fund to channel Chinese healthcare ventures into US markets via a VIE structure tied to SPAC Longevity Acquisition...
Puhui Brilliance Fund
Puhui Brilliance Fund is a Beijing-based investment company that employs a Venture Capital strategy.
General information
Firm type
Generalist
Year founded
—
AUM
Undisclosed
Location
Region
Asia
Country
China
City
Beijing
Corporate office
Beijing, China
Principals
Zhe Ji
Founder, Chairman, and CEO
Sector focus
Frequently asked questions
Who controls investment decisions at Puhui Brilliance Fund?
Zhe Ji, as Founder, Chairman, and CEO of parent entity Puhui Wealth Investment Management, maintained investment authority over the fund's venture allocations. A broader investment committee has not been disclosed in public filings.
How did the fund source its healthcare investments?
The fund sourced deals domestically within China, leveraging the parent company's VIE structure and onshore network to identify healthcare companies seeking cross-border capital. Specific sourcing channels, including any formal incubator or hospital-system partnerships, have not been publicly detailed.
What was the relationship between Puhui Brilliance Fund and Longevity Acquisition Corporation?
Longevity Acquisition Corporation was an affiliated SPAC sponsored by entities related to Puhui Wealth Investment Management. It functioned as a designated exit vehicle, targeting high-growth companies — including those within Puhui's pipeline — for Nasdaq listings via de-SPAC business combinations.
Is Puhui Brilliance Fund still actively investing?
The firm's operational status is opaque. Its parent, Puhui Wealth Investment Management, faced financial distress and regulatory headwinds beginning in 2021 as China moved to restrict VIE-based wealth management structures. The fund's current deal-making posture is unclear.
What regulatory risk was embedded in Puhui's structure?
Puhui's reliance on a VIE structure for domestic operations combined with a US-listed SPAC exit vehicle placed it directly in the path of two regulatory crackdowns: China's prohibition on new VIE formations for asset management and tightened oversight of offshore listings, both of which materially constrained the fund's strategic playbook after 2021.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: